Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Seeking Alpha
BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end. BCAX is well-capitalized, with more than $414.8M in cash and funding runway into H1 2029, but faces competitive risk from Genmab's petosemtamab and trial readouts. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thicha Satapitanon/iStock via Getty Images The last time I spoke about Bicara Therapeutics Inc. ( BCAX ), it was in a Seeking Alpha article entitled " Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity ." With respect More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharm
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its price target raised by HC Wainwright from $40.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- BCAX's page on the SEC website